KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $190.2 million.

  • Gsk's Non Operating Income rose 122614.32% to $190.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.5 million, marking a year-over-year increase of 25355.26%. This contributed to the annual value of $699.2 million for FY2024, which is 1696.44% down from last year.
  • According to the latest figures from Q3 2025, Gsk's Non Operating Income is $190.2 million, which was up 122614.32% from $178.8 million recorded in Q2 2025.
  • Over the past 5 years, Gsk's Non Operating Income peaked at $446.9 million during Q4 2022, and registered a low of -$1.0 billion during Q4 2021.
  • For the 5-year period, Gsk's Non Operating Income averaged around $1.6 million, with its median value being $136.0 million (2025).
  • As far as peak fluctuations go, Gsk's Non Operating Income plummeted by 49696.48% in 2021, and later soared by 122614.32% in 2025.
  • Gsk's Non Operating Income (Quarter) stood at -$1.0 billion in 2021, then surged by 143.74% to $446.9 million in 2022, then fell by 9.46% to $404.6 million in 2023, then fell by 9.91% to $364.5 million in 2024, then tumbled by 47.82% to $190.2 million in 2025.
  • Its Non Operating Income was $190.2 million in Q3 2025, compared to $178.8 million in Q2 2025 and $136.0 million in Q1 2025.